Hjem › Pladecellekræft i hoved og hals › Oklahoma
Pladecellekræft i hoved og hals kliniske forsøg i Oklahoma
14 studier for Pladecellekræft i hoved og hals søger deltagere på steder i Oklahoma.
Byer i Oklahoma
Officiel studietekst (engelsk)
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06992427Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT06589804BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT05136196JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
- Stephenson Cancer Center, Oklahoma City
RekruttererFase 3
Alder 60 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT04892173Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 2
Alder 18 til 79 · Alle køn · Opdateret 22. sep. 2026 · NCT04671667Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 14. sep. 2026 · NCT02734537A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Oklahoma City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 18. aug. 2026 · NCT07182149Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 17. aug. 2026 · NCT04333537Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 17. aug. 2026 · NCT06532279A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- SSM OKC Hightower Clinical, Oklahoma City
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 29. jul. 2026 · NCT03526835A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 6. jul. 2026 · NCT04389632A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- GSK Investigational Site, Tulsa
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 26. maj 2026 · NCT06256588A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Oklahoma City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 7. jan. 2026 · NCT06999187A Study of NX-1607 in Adults With Advanced Malignancies
- University of Oklahoma, Oklahoma City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2025 · NCT05107674Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.